Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Roivant Sciences (ROIV) Total Liabilities (2020 - 2025)

Roivant Sciences' Total Liabilities history spans 6 years, with the latest figure at $251.1 million for Q4 2025.

  • For Q4 2025, Total Liabilities fell 2.04% year-over-year to $251.1 million; the TTM value through Dec 2025 reached $251.1 million, down 2.04%, while the annual FY2025 figure was $249.7 million, 67.73% down from the prior year.
  • Total Liabilities reached $251.1 million in Q4 2025 per ROIV's latest filing, down from $257.1 million in the prior quarter.
  • In the past five years, Total Liabilities ranged from a high of $822.5 million in Q2 2022 to a low of $216.7 million in Q2 2025.
  • Average Total Liabilities over 5 years is $564.6 million, with a median of $613.6 million recorded in 2024.
  • Peak YoY movement for Total Liabilities: soared 127.01% in 2021, then tumbled 67.73% in 2025.
  • A 5-year view of Total Liabilities shows it stood at $529.6 million in 2021, then surged by 46.49% to $775.8 million in 2022, then dropped by 6.15% to $728.1 million in 2023, then plummeted by 64.79% to $256.4 million in 2024, then dropped by 2.04% to $251.1 million in 2025.
  • Per Business Quant, the three most recent readings for ROIV's Total Liabilities are $251.1 million (Q4 2025), $257.1 million (Q3 2025), and $216.7 million (Q2 2025).